Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma
Authors:
- 1 November 2021
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 100, 108161
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Jilin Province (20190201047JC, 20200201482JC)
This publication has 32 references indexed in Scilit:
- A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell linesOncoImmunology, 2014
- Intraepithelial Type 1 Innate Lymphoid Cells Are a Unique Subset of IL-12- and IL-15-Responsive IFN-γ-Producing CellsImmunity, 2013
- Living in the liver: hepatic infectionsNature Reviews Immunology, 2012
- The composition and signaling of the IL-35 receptor are unconventionalNature Immunology, 2012
- Dual effects of interleukin-18: inhibiting hepatitis B virus replication in HepG2.2.15 cells and promoting hepatoma cells metastasisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2011
- CD8+ T Cell Control of Hepatitis B Virus Replication: Direct Comparison between Cytolytic and Noncytolytic FunctionsThe Journal of Immunology, 2009
- The inhibitory cytokine IL-35 contributes to regulatory T-cell functionNature, 2007
- IL‐35 is a novel cytokine with therapeutic effects against collagen‐induced arthritis through the expansion of regulatory T cells and suppression of Th17 cellsEuropean Journal of Immunology, 2007
- α-Fetoprotein and Interleukin-18 Gene–Modified Dendritic Cells Effectively Stimulate Specific Type-1 CD4- and CD8-Mediated T-Cell Response from Hepatocellular Carcinoma Patients in VitroHuman Immunology, 2007
- Defective NK Cell Activity and Th1 Response in IL-18–Deficient MiceImmunity, 1998